Skip to main content
Tanvex logo

Tanvex — Investor Relations & Filings

Ticker · 6541 ISIN · KYG8676P1037 TW Manufacturing
Open in API
Filings indexed 26 across all filing types
Latest filing 2026-05-19 Audit Report / Informat…
Country TW Taiwan
Listing TW 6541

About Tanvex

www.tanvex.com

Tanvex BioPharma, Inc. specializes in the research, development, manufacturing, and commercialization of biosimilars and innovative biologics. The company operates a vertically integrated model encompassing cell line development, process optimization, and clinical to commercial-scale production. Its portfolio focuses on biosimilars for oncology and supportive care, alongside emerging Antibody-Drug Conjugate (ADC) programs. Tanvex provides comprehensive Contract Development and Manufacturing Organization (CDMO) services, offering a unified platform that supports early-stage development through to commercial manufacturing. By maintaining GMP-compliant facilities and achieving regulatory approval for its biosimilar products, the company delivers end-to-end solutions aimed at increasing the accessibility of safe and effective treatments in international markets.

Recent filings

Filing Released Lang Actions
114年第4季財務報告書 — 202504_6541_AIA.pdf
Audit Report / Information Classification · 93% confidence The document is an Independent Auditors’ Report together with consolidated financial statements for the years ended December 31, 2025 and 2024. It comprises a standalone audit opinion, key audit matters, basis of opinion, and detailed auditor responsibilities, and does not include the full narrative and management discussion typical of an Annual Report. Therefore, it fits the definition of a standalone Audit Report / Information. FY 2025
2026-05-19 English
114年第4季財務報告書 — 202504_6541_AI1.pdf
Audit Report / Information Classification · 90% confidence The document is the consolidated financial statements of 泰福生技股份有限公司及子公司 for the fiscal years 113 and 114 (ROC), accompanied by the independent auditors’ report from PwC (資誠聯合會計師事務所). It includes the auditor’s opinion, detailed notes to the financial statements, and full audited balance sheet, income statement, cash flow statement, etc. It is a standalone audit report with the audited consolidated financial statements and contains substantive financial data and audit opinions. This matches the description of an Audit Report / Information (Code: AR), rather than an Annual Report (10-K) or an announcement. FY 2025
2026-05-19 Chinese
114年第4季財務報告書 — 202503_6541_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled “合併財務報告暨會計師核閱報告 民國114年及113年第三季,” which translates to a consolidated financial report and auditor’s review for the third quarter of fiscal years 114 and 113. It contains the auditor’s review opinion under Taiwanese GAAP/IFRS 34 “Interim Financial Reporting,” as well as full interim financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement) and detailed notes. This is a comprehensive quarterly/interim financial report with substantive data—not merely an announcement—so it matches the definition of an Interim / Quarterly Report (Code: IR). 9M 2025
2026-05-19 Chinese
114年第4季財務報告書 — 202502_6541_AI1.pdf
Interim / Quarterly Report Classification · 92% confidence The document is a consolidated financial report for the second quarter of fiscal years 114 and 113, including the auditor’s opinion, consolidated balance sheets, income statements, cash flow statements, notes, and key audit matters prepared under IFRS 34 “Interim Financial Reporting.” It contains substantive financial data for a period shorter than a full fiscal year, not merely an announcement. This matches the definition of an Interim/Quarterly Report. Q2 2025
2026-05-19 Chinese
114年第4季財務報告書 — 202501_6541_AI1.pdf
Interim / Quarterly Report Classification · 92% confidence The document is a full consolidated interim financial report for the first quarter (民國114年及113年第一季) of the company and its subsidiaries, including audited/reviewed financial statements (balance sheet, income statement, cash flow statement), extensive notes, and an auditor’s review report by PwC. It is not merely an announcement or link to a report, nor is it a press release or earnings summary. It meets the criteria for a comprehensive quarterly/interim report under IFRS. Therefore, it should be classified as an Interim/Quarterly Report. Q1 2025
2026-05-19 Chinese
115年第1季財務報告書 — 202601_6541_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled as a consolidated financial report (“合併財務報告暨會計師核閱報告”) for the first quarter (民國115年及114年第一季), including an auditor’s review opinion and full interim financial statements (balance sheet, income statement, equity changes, cash flows) with detailed notes. This aligns with an Interim/Quarterly Report. It is the report itself rather than an announcement of publication. Q1 2026
2026-05-15 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.